Thymalin vs LL-37

Thymalin wins for: Broad-spectrum immune normalization, longevity protocols, rebounding immune function post-suppression, exceptionally well-tolerated profile, and a deep safety bench from decades of Russian clinical use. Acute, pulsed dosing fits well for reset or annual anti-aging stacks.

LL-37 wins for: Potent, broad-spectrum antimicrobial activity—especially against resistant bacterial, fungal, and viral pathogens—plus direct biofilm disruption and accelerated wound healing. Especially effective in protocols where stubborn infections or impaired tissue repair are the primary target. LL-37's efficacy is unmatched for topical use in post-procedure wound care or chronic skin conditions, but it requires careful management of its pro-inflammatory risk.

Pick Thymalin if:

• The goal is full-spectrum immune normalization after immune suppression (e.g., post-AAS, chronic stress recovery).
• Annual or semi-annual longevity/geroprotective stacking (a la Khavinson protocols) is planned.
• A history of frequent minor infections or sluggish recovery hints at low-grade immune system drift.
• A well-characterized, logistically easy course with a known safety record is preferred.
• Epithalon stacking for enhanced lifespan and healthspan signaling is on the table.

Pick LL-37 if:

• Protocols target chronic, resistant, or biofilm-protected infections that have failed conventional therapies.
• There is a need to rapidly accelerate wound healing (surgical, injury, post-hair transplant, or stubborn ulcers).
• Topical application is needed for cystic acne, recalcitrant skin infections, or post-procedure healing.
• BPC-157/TB-500 aren't covering infection or persistent inflammation in soft tissue.
• Research aims to investigate antimicrobial/antiviral/fungal protection in an innate-immune context, not just immune modulation.